Herlab
HERlab is a synbio and AI startup that utilizes unconventional microorganisms and LLM to develop specialized microbial expression systems for complex protein production. Based in the UK, the company focuses on scaling up production of proteins requiring human-like glycosylation and other human-origin proteins that have not been industrially produced before. HERlab aims to assist pharmaceutical, cosmetics, and protein engineering companies with novel or complex protein production needs, leveraging their innovative platform to produce challenging recombinant proteins in under 10 weeks.
Herlab
HERlab is a synbio and AI startup that utilizes unconventional microorganisms and LLM to develop specialized microbial expression systems for complex protein production. Based in the UK, the company focuses on scaling up production of proteins requiring human-like glycosylation and other human-origin proteins that have not been industrially produced before. HERlab aims to assist pharmaceutical, cosmetics, and protein engineering companies with novel or complex protein production needs, leveraging their innovative platform to produce challenging recombinant proteins in under 10 weeks.
TL;DR
What they do: AI-guided synthetic biology platform that uses a library of unconventional yeasts/microorganisms to produce complex recombinant proteins.
Founded: 2022
Headquarters: United Kingdom (registered office in St Dominick; third-party profiles list London or Saltash)
Funding: 230,000 USD total; investor Katapult Group (last funding date: 2023-10-07)
Team size: 12 employees
Company Overview
Problem Domain
Complex recombinant protein expression and production of proteins requiring specific post-translational modifications (including human-like glycosylation).
Founded
2022
Industry
Biotechnology
Tech Stack
Funding Track Record
230,000 USD
Listed in third-party databases as a Katapult-associated support program / pre-seed funding entry.
Investor Signal
“Katapult Group (investor / support-program participant)”